Answers are grounded in this paper and cite their sources.
Chemotherapy induced nausea and vomiting (CINV) is a side effect and has negative effect on quality of life and continuation of chemotherapy.Despite new regimen and drugs, the problem still remains and there is no standard guidelines, effective treatment and supportive care for refractory CINV.Persian medicine, the old Iranian medical school, offers Persumac (prepared from Rhus Coriaria and Bunium Persicum boiss) for this problem.The objective of this study was to evaluate effect of Persumac on on number and severity of nausea and vomiting in refractory CINV in acute and delayed phase.This randomized, double blind, cross over clinical trial study was carried out on 93 patients with breast cancer and refractory CINV who received outpatient high emetogenic chemotherapy in Imam Reza Hospital, Mashhad, Iran from October 2015 to May 2016.The study has three stages: in stage I, patients received a questionnaire and filled it after chemotherapy.In stage II, they were randomly divided to intervention group with Persumac and control group with placebo (lactose).In stage III, wash out and cross over were conducted.The mean number and severity of nausea and vomiting scores were significantly decreased in the delayed phase of CINV by Persumac.
No takes yet. Share an insight, caveat, or question.
Mobarra et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: